Sepracor Inc announced that the Board of Patent Appeals and Interferences (BPAI) of the US Patent and Trademark Office has combined three patent interferences into a single interference between Sepracor and Wyeth and set a date for oral arguments. The interference seeks to determine the priority of inventorship of claims directed to racemic O-desmethylvenlafaxine (ODMV) succinate. Wyeth markets racemic ODMV succinate in the US under the brand name Pristiq for the treatment of major depressive disorder in adults.
The details can be read here.
No comments:
Post a Comment